Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.58 |
| ▸ | DRD2 | P14416 | 5/20 | 0.44 |
| ▸ | DRD3 | P35462 | 5/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 2/20 | 0.40 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12064538 | 1.00 | DPP4 (0.58) | DPP4DRD2DRD3DPP8DPP7 | |
| SCHEMBL14722978 | 1.00 | DPP4 (0.58) | DPP4DRD2DRD3DPP8DPP7 | |
| SCHEMBL149732 | 0.91 | DPP4 (0.64) | DPP4DRD2DRD3DPP8DPP7 | |
| SCHEMBL149731 | 0.91 | DPP4 (0.64) | DPP4DRD2DRD3DPP8DPP7 | |
| SCHEMBL149730 | 0.91 | DPP4 (0.64) | DPP4DRD2DRD3DPP8DPP7 | |
| SCHEMBL461966 | 0.91 | DPP4 (0.64) | DPP4DRD2DRD3DPP8DPP7 | |
| SCHEMBL470654 | 0.86 | DPP4 (0.60) | DPP4DRD2DRD3CCR5ACHE | |
| SCHEMBL1203772 | 0.84 | DPP4 (0.60) | DPP4DRD2DRD3CCR5FUCA1 | |
| SCHEMBL1203774 | 0.84 | DPP4 (0.60) | DPP4DRD2DRD3CCR5FUCA1 | |
| SCHEMBL1725958 | 0.83 | DPP4 (0.63) | DPP4DRD2DRD3CCR5FUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013026587-A1 | 1,4 DISUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2013-02-28 | — | — | WO | disclosed |